Original document(4 pages)  中文版
    The invention relates to an alpha-interferon plasmid DNA-liposome preparation making method. It sub-clones the alpha-interferon plasmid DNA in true nucleus expression carrier pSG5 to make expression plasmid, then mixes dilaurin (GDL), cholesterin (CH), polyoxyethylene stearate (POE-10), polyvinyl -pyrrolidone (PVP) and alpha-tocopherol to dissolve at 70 deg.C, filters by 0.22mum microhole film, then heats to 70 deg.C, slowly drips 70 deg.C aseptic water in the lipid mixture to make the total lipid concentration not less than 1g/ml, quickly evenly mixes two phases to cool to room temperature, then stores the liposome at 4 deg.C for ultrasonic processing at room temperature, adds in equal bulk of water solution with the expression plasmid, and evenly mixes to hatch to obtain the preparation.
Application Number
申请号
03146998 Application Date
申请日
2003.09.29
Title 名称 Method for preparing alpha-interferon plasmid DNA-liposome preparation
Publication Number
公开号
1528464 Publication Date
公开日
2004.09.15
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K9/127,A61K48/00,A61P17/12,A61P31/12
Applicant(s) Name
申请人
Zhongshan Univ.
Address 地址 510275
Inventor(s) Name 发明人 Su Weiwei, Ji Aimin
Attorney & Agent 代理人

  
Naringin used in preparing medicine for curing acute and chronic bronchitis
Method for extracting naringin
Health care food for regulating immunity, antioxidation and its preparing method
'Huajuhong' preparation and its preparing process
Method for extracting quercetin-7-0-rhamnoside
Method for extracting shaddock ped aglycone from shaddock
Method for constituting finger-print pyrogram of white atracty lodes and its standard finger-print pyrogram
Method for constituting TLC finger-print pyrogram of hypericum-japonicum medicinal herbs and its standard finger-print pyrogram
Application of naringin in preparing medicine for supporting treatment of SARS
Medicine composition for treating diabetes and its preparation
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.